Vise Technologies Inc. Takes $356,000 Position in argenex SE $ARGX

Vise Technologies Inc. bought a new position in shares of argenex SE (NASDAQ:ARGX) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 646 shares of the company’s stock, valued at approximately $356,000.

A number of other institutional investors also recently made changes to their positions in the stock. WPG Advisers LLC acquired a new stake in shares of argenex during the first quarter valued at $37,000. Brooklyn Investment Group boosted its stake in shares of argenex by 102.7% during the 1st quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock worth $44,000 after purchasing an additional 38 shares during the last quarter. Banque Transatlantique SA purchased a new stake in shares of argenex during the first quarter worth about $62,000. Geneos Wealth Management Inc. raised its position in shares of argenex by 550.0% in the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after buying an additional 99 shares during the last quarter. Finally, Raiffeisen Bank International AG purchased a new position in shares of argenex during the first quarter valued at approximately $76,000. 60.32% of the stock is owned by institutional investors and hedge funds.

argenex Stock Up 1.8%

argenex stock opened at $907.98 on Monday. The firm has a fifty day moving average of $799.34 and a 200-day moving average of $672.81. argenex SE has a 52-week low of $510.05 and a 52-week high of $914.87. The firm has a market capitalization of $55.90 billion, a P/E ratio of 38.99, a PEG ratio of 0.93 and a beta of 0.45.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, October 30th. The company reported $4.40 earnings per share for the quarter, topping analysts’ consensus estimates of $4.37 by $0.03. argenex had a net margin of 41.58% and a return on equity of 29.78%. The firm had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.07 billion. On average, research analysts expect that argenex SE will post 3.13 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ARGX shares. Piper Sandler raised their price objective on argenex from $820.00 to $930.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Bank of America upped their price objective on shares of argenex from $880.00 to $887.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. TD Cowen boosted their target price on shares of argenex from $800.00 to $1,146.00 and gave the company a “buy” rating in a report on Friday, October 31st. Deutsche Bank Aktiengesellschaft downgraded shares of argenex from a “buy” rating to a “hold” rating in a research note on Thursday, September 11th. Finally, Evercore ISI boosted their price objective on shares of argenex from $775.00 to $910.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $885.94.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.